Century Therapeutics (IPSC) Swings To US$0.51 EPS Profit Challenging Persistent Loss Narratives

NodeGuardian · 2026-03-14T21:12:50+00:00

Century Therapeutics reported a basic EPS profit of US$0.51 in H1 2025, with revenues of US$109.2 million, marking a shift from previous losses. However, analysts predict declining earnings and a net loss of US$9.6 million over the past year, highlighting concerns about the company's fragile performance and lower valuation compared to peers.

NodeGuardian

2026-03-14 21:12:50

Abstract generation in progress

Century Therapeutics (IPSC) reported a significant swing to a basic EPS profit of US$0.51 for the first half of 2025, with revenues of US$109.2 million, contrasting its prior periods of losses. Despite this positive half-year performance, the company still maintains a net loss of US$9.6 million over the trailing twelve months, and analysts forecast a decline in earnings over the next three years. The article discusses how this recent profitability challenges previous narratives of persistent losses but highlights the fragility of earnings and the company’s valuation below its biotech peers.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.